Repair & immune · Research peptide
Also known as Body Protection Compound 157, PL 14736
A synthetic fifteen-amino-acid peptide studied mainly in laboratory and animal models. It is not an FDA-approved drug.[1]
The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome. This is a description, not a rating or recommendation.
Recovery and inflammatory research
The systematic review found that the evidence base was dominated by animal studies, with very limited human data and no basis for routine clinical conclusions.
Human effectiveness, long-term safety, pharmacokinetics, manufacturing consistency, and the relevance of animal findings are unresolved. Lack of robust human trials is an absence of evidence, not proof of no biological activity.
Animal studies report effects in musculoskeletal and gastrointestinal injury models. These findings are hypothesis-generating and do not establish healing, safety, or effectiveness in people.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
FDA identifies potential immunogenicity, peptide-impurity, and API-characterization concerns and states that it has only limited safety information for proposed routes. Products sold outside regulated trials add identity, sterility, and contamination risks.
Research or cosmetic products may add identity, strength, purity, sterility, contamination, or formulation concerns. This is separate from the evidence about the compound itself.Source [1]Human effectiveness, long-term safety, pharmacokinetics, manufacturing consistency, and the relevance of animal findings are unresolved. Lack of robust human trials is an absence of evidence, not proof of no biological activity.
Human outcomes, long-term safety, formulation identity, and product consistency remain limited or unresolved in the cited material.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
No FDA-approved formulation or route exists. Descriptions of experimental preparations are not instructions for use.
No FDA-approved route exists. Research-route descriptions vary and are not instructions for use.
U.S. product context
No FDA-approved medicine was identified for this defined material. Research findings and products sold outside reviewed trials should not be treated as approval.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
BPC-157 is not an FDA-approved drug. FDA has identified it among bulk substances for which compounded use may present significant safety risks.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
Systematic review of BPC-157 in orthopaedic sports medicine
Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. 2025.
PubMed-indexed systematic review · Published Jul 31, 2025 · Accessed Jul 22, 2026 · Systematic review
Open sourceFDA: Certain bulk drug substances may present significant safety risks
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
U.S. Food and Drug Administration · Published Jul 22, 2026 · Accessed Jul 22, 2026 · Regulatory source
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
